Skip to content
Industry
This is research, not advice. We’re not SEBI-registered.

Vijaya Diagnostic Centre share price today

VIJAYADiagnosticsConsolidatedPrices to 13 Nov 2026Results to Sep 2026

Price, 200-day average and NIFTY 500

The price is 8.7% above its 200-day average and 96 points ahead of the NIFTY 500 over 5 years

13 Nov 2026₹1,410.10Over 5 years: Vijaya Diagnostic Centre +149.3%, NIFTY 500 +53.2%
₹500₹1,000Nov 22Nov 24Nov 26

Price growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y+33.0%3Y+30.2%/yr5Y+20.0%/yr10YToo short

EPS and P/E

EPS ₹19.79, up 34% in a year; P/E 71.3

13 Nov 2026₹19.79 EPS
Mar 22
Jun 22
Sep 22
Dec 22
Mar 23
Jun 23
Sep 23
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
Nov 26
₹0₹30

EPS growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y+33.7%3Y+25.1%/yr5Y+19.1%/yr10YToo short

Revenue and marginsInsufficient history, from Mar 2018

Revenue up on a year for 12 quarters in a row; operating margin 44.3%, the highest on this chart

Sep 2026 quarter₹255 crore+26.2% on ₹202 crore a year earlier · NPM 23.1%
Dec 22
Mar 23
Jun 23
Sep 23
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
0₹300

Revenue: 1Y change, then growth a year; margins are averages

Revenue growth1Y+24.3%3Y+22.6%/yr5Y+16.6%/yr to Mar10YToo short
OPM average3Y41.3%5Y41.1% to Mar
NPM average3Y21.6%5Y21.4% to Mar

Return on capitalInsufficient history, from Mar 2019

ROCE was 22.3% for the four quarters to Sep 2026, down from 28.3% in the year to Mar 2022

Four quarters to Sep 202622.3% ROCE
15%25%Sep 22Sep 24Sep 26

ROCE average

1Y3Y5Y10Y1Y22.3%3Y21.0% to Mar5Y22.0% to Mar10YToo short

Profit and cashInsufficient history, from Mar 2018

Cash from operations was 158% of profit over five years, 157% in the year to Mar 2026

Yearly profit, cash from operations and free cash flow, ₹ crore

FY26₹271 crore operating cashProfit ₹173 crore · Free cash ₹88 crore
FY22
FY23
FY24
FY25
FY26
0₹300

Profit growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y+33.6%3Y+25.0%/yr5Y+15.3%/yr to Mar10YToo short

ReinvestmentInsufficient history, from Mar 2018

Capex was ₹183 crore in the year to Mar 2026, 2.0 times depreciation

FY26₹183 crore capexWork in progress ₹35 crore
FY22
FY23
FY24
FY25
FY26
0₹200

Capex growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y+91.2% to Mar3Y+13.5%/yr to Mar5YToo short10YToo short

BorrowingsInsufficient history, from Dec 2022Insufficient history, from Dec 2022

Debt ÷ equity 0.48 at 30 Sep 2026; profit covered interest 7.8x over the last four quarters

Sep 2026 balance sheet0.48 debt ÷ equityNet debt ₹160 crore
Dec 22
Mar 23
Jun 23
Sep 23
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
012.5x

Safety

Now3Y ago
Debt ÷ equity0.483Y ago0.42
Int. cover7.8x3Y ago6.8x

Operating health

Working capital fell from -26 to -37 days in 5 years; below zero, customers' advance payments and other dues are larger than the money tied up in the business

Year to Mar 2026-37 days working capital
-4020Mar 22Mar 24Mar 26
Working cap.-371Y+113Y−15Y−11
Debtor91Y+13Y+15Y+3
Inventory191Y−23Y+65Y+2

OwnershipInsufficient history, from Mar 2023Insufficient history, from Mar 2023

FIIs own 10.67%, down 7.60 points in a year. Promoters hold 52.46%

Share of the company held, %, by quarter end

Sep 2026 quarter10.67% FIIs
20%40%Sep 23Sep 24Sep 25Sep 26

Change in holding, in points

FIIs1Y−7.603Y−10.01
Promoters1Y−0.143Y−2.44

Vijaya Diagnostic Centre Ltd · VIJAYA · Diagnostics · price as of the 13 November 2026 close, updated every trading day · results updated weekly · research updated 22 August 2026

Vijaya Diagnostic Centre share price today: ₹1,410.10 at the close on 13 November 2026, up 33.0% in a year. Vijaya Diagnostic Centre (VIJAYA) is worth ₹14,520 crore, trades at a P/E of 71.3 and has closed between ₹870.30 and ₹1,558.90 over the past 52 weeks. Latest change: foreign funds (FIIs) cut their stake for 5 quarters in a row.

Growing steadilyBusiness trend from the last 12 quarters
₹1,410.10Price +33.0% in a year
71.3×P/E higher than 71% of the last 5.1 years
₹255 CrRevenue (Sep 2026) +26.2% on a year ago
₹59.0 CrProfit (Sep 2026) +37.2% on a year ago
44.3%Operating margin +3.7 points on a year ago
22.3%ROCE four quarters to Sep 2026
19.5%ROIC against a 12.0% cost of capital: +7.5 points

Vijaya Diagnostic Centre Ltd's earnings have grown faster than its share price. Earnings per share grew +33.7% in a year while the price moved +33.0%.

The main question: foreign institutions moved −7.5 percentage points over 8 quarters while the business went the other way.

The price has been rising for 26 weeks, and the P/E is higher than 71% of its own last 5.1 years. Over the last four quarters, results have been improving, with profit +37.2% on a year earlier, and 155% of the last 3 years' profit came in as cash. What will decide it: whether the owners’ moves turn back in line with the business.

Our note on Vijaya Diagnostic Centre's latest quarter, with what management said on the call, is in the Sector Alpha newsletter.

What is the Vijaya Diagnostic Centre share price today?

Vijaya Diagnostic Centre Ltd's share price was ₹1,410.10 at the close on 13 November 2026. It has been rising for 26 weeks. That is 8.7% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹870 and ₹1,559, and at that close it sat 78% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Vijaya Diagnostic Centre Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 1 week running.

Week by week since 2021: did it beat the NIFTY 500 over the past 13 weeks?

Ahead in 142 of 264 weeks

Week by week since 2021: did it beat the NIFTY 500 over the past 13 weeks?
Week13-week return vs NIFTY 500
17 Sep 2021no NIFTY 500 reading
24 Sep 2021no NIFTY 500 reading
1 Oct 2021no NIFTY 500 reading
8 Oct 2021no NIFTY 500 reading
14 Oct 2021no NIFTY 500 reading
22 Oct 2021no NIFTY 500 reading
29 Oct 2021no NIFTY 500 reading
4 Nov 2021no NIFTY 500 reading
12 Nov 2021no NIFTY 500 reading
18 Nov 2021no NIFTY 500 reading
26 Nov 2021no NIFTY 500 reading
3 Dec 2021no NIFTY 500 reading
10 Dec 2021no NIFTY 500 reading
17 Dec 2021−11.3%
24 Dec 2021−6.6%
31 Dec 2021+3.9%
7 Jan 2022−3.2%
14 Jan 2022−1.8%
21 Jan 2022−4.6%
28 Jan 2022−9.6%
4 Feb 2022−6.9%
11 Feb 2022−12.0%
18 Feb 2022−20.2%
25 Feb 2022−25.7%
4 Mar 2022−19.2%
11 Mar 2022−23.4%
17 Mar 2022−23.3%
25 Mar 2022−18.0%
1 Apr 2022−23.5%
8 Apr 2022−15.9%
13 Apr 2022−16.6%
22 Apr 2022−15.9%
29 Apr 2022−4.5%
6 May 2022−10.1%
13 May 2022−9.5%
20 May 2022−1.9%
27 May 2022−6.9%
3 Jun 2022−15.9%
10 Jun 2022−14.7%
17 Jun 2022−8.5%
24 Jun 2022−14.4%
1 Jul 2022−9.8%
8 Jul 2022−21.5%
15 Jul 2022−21.5%
22 Jul 2022−21.3%
29 Jul 2022−28.7%
5 Aug 2022−16.2%
12 Aug 2022−21.6%
19 Aug 2022−23.0%
26 Aug 2022−15.2%
2 Sep 2022−3.7%
9 Sep 2022+19.3%
16 Sep 2022+5.0%
23 Sep 2022+19.4%
30 Sep 2022+21.5%
7 Oct 2022+38.6%
14 Oct 2022+27.2%
21 Oct 2022+33.8%
28 Oct 2022+28.6%
4 Nov 2022+24.8%
11 Nov 2022+27.7%
18 Nov 2022+27.4%
25 Nov 2022+23.0%
2 Dec 2022+18.5%
9 Dec 2022−2.0%
16 Dec 2022+5.1%
23 Dec 2022+0.4%
30 Dec 2022−8.0%
6 Jan 2023−18.6%
13 Jan 2023−7.6%
20 Jan 2023−11.0%
27 Jan 2023−6.0%
3 Feb 2023−10.1%
10 Feb 2023−0.3%
17 Feb 2023−4.5%
24 Feb 2023−9.6%
3 Mar 2023−8.0%
10 Mar 2023+0.1%
17 Mar 2023−4.5%
24 Mar 2023−7.6%
31 Mar 2023−6.0%
6 Apr 2023+3.2%
13 Apr 2023−1.1%
21 Apr 2023−8.4%
28 Apr 2023−10.2%
5 May 2023−13.9%
12 May 2023−17.8%
19 May 2023−15.1%
26 May 2023−6.4%
2 Jun 2023−12.5%
9 Jun 2023−15.1%
16 Jun 2023−7.2%
23 Jun 2023+9.3%
30 Jun 2023+8.0%
7 Jul 2023+7.8%
14 Jul 2023+4.6%
21 Jul 2023+8.1%
28 Jul 2023+9.8%
4 Aug 2023+12.6%
11 Aug 2023+18.5%
18 Aug 2023+15.6%
25 Aug 2023+22.9%
1 Sep 2023+24.5%
8 Sep 2023+15.6%
15 Sep 2023+13.8%
22 Sep 2023−10.1%
29 Sep 2023+2.4%
6 Oct 2023+0.8%
13 Oct 2023+17.9%
20 Oct 2023+26.9%
27 Oct 2023+25.1%
3 Nov 2023+24.4%
12 Nov 2023+29.0%
17 Nov 2023+23.7%
24 Nov 2023+18.3%
1 Dec 2023+16.3%
8 Dec 2023+18.9%
15 Dec 2023+16.7%
22 Dec 2023+29.4%
29 Dec 2023+22.3%
5 Jan 2024+24.3%
12 Jan 2024+8.5%
20 Jan 2024−2.6%
25 Jan 2024−3.5%
2 Feb 2024−4.6%
9 Feb 2024−12.1%
16 Feb 2024−7.8%
23 Feb 2024−4.3%
2 Mar 2024−4.9%
7 Mar 2024−0.5%
15 Mar 2024−5.7%
22 Mar 2024−5.7%
28 Mar 2024−12.2%
5 Apr 2024−8.7%
12 Apr 2024−2.7%
19 Apr 2024−2.2%
26 Apr 2024+2.4%
3 May 2024+2.1%
10 May 2024+20.5%
18 May 2024+21.7%
24 May 2024+12.4%
31 May 2024+22.0%
7 Jun 2024+15.4%
14 Jun 2024+17.9%
21 Jun 2024+10.8%
28 Jun 2024+6.7%
5 Jul 2024+8.6%
12 Jul 2024+1.2%
19 Jul 2024+2.4%
26 Jul 2024+0.9%
2 Aug 2024+5.0%
9 Aug 2024−6.0%
16 Aug 2024−8.6%
23 Aug 2024+7.5%
30 Aug 2024−0.6%
6 Sep 2024+6.2%
13 Sep 2024+8.2%
20 Sep 2024+7.4%
27 Sep 2024+11.3%
4 Oct 2024+22.8%
11 Oct 2024+24.1%
18 Oct 2024+31.3%
25 Oct 2024+17.3%
1 Nov 2024+23.3%
8 Nov 2024+38.3%
14 Nov 2024+32.5%
22 Nov 2024+36.5%
29 Nov 2024+30.6%
6 Dec 2024+24.9%
13 Dec 2024+23.7%
20 Dec 2024+24.3%
27 Dec 2024+29.9%
3 Jan 2025+18.3%
10 Jan 2025+34.5%
17 Jan 2025+15.0%
24 Jan 2025+14.7%
1 Feb 2025+17.1%
7 Feb 2025+5.9%
14 Feb 2025−5.4%
21 Feb 2025−8.5%
28 Feb 2025−9.2%
7 Mar 2025+5.5%
13 Mar 2025+1.3%
21 Mar 2025+3.4%
28 Mar 2025−1.3%
4 Apr 2025−6.3%
11 Apr 2025−21.6%
17 Apr 2025−7.8%
25 Apr 2025+2.4%
2 May 2025−9.8%
9 May 2025−20.0%
16 May 2025−10.9%
23 May 2025−19.9%
30 May 2025−8.2%
6 Jun 2025−22.6%
13 Jun 2025−16.1%
20 Jun 2025−18.8%
27 Jun 2025−12.5%
4 Jul 2025−8.1%
11 Jul 2025−4.0%
18 Jul 2025−6.6%
25 Jul 2025−1.5%
1 Aug 2025+6.0%
8 Aug 2025+5.3%
14 Aug 2025+13.9%
22 Aug 2025+12.1%
29 Aug 2025+5.1%
5 Sep 2025+14.7%
12 Sep 2025+7.3%
19 Sep 2025+14.2%
26 Sep 2025+5.7%
3 Oct 2025+1.0%
10 Oct 2025−3.5%
17 Oct 2025−4.9%
24 Oct 2025−11.6%
31 Oct 2025−13.2%
7 Nov 2025−7.9%
14 Nov 2025−2.6%
21 Nov 2025−6.6%
28 Nov 2025−4.7%
5 Dec 2025−9.6%
12 Dec 2025−5.1%
19 Dec 2025−8.6%
26 Dec 2025−2.6%
2 Jan 2026+0.8%
9 Jan 2026+0.8%
16 Jan 2026+3.5%
23 Jan 2026+4.3%
1 Feb 2026+0.2%
6 Feb 2026−5.5%
13 Feb 2026−5.7%
20 Feb 2026+2.5%
27 Feb 2026+6.2%
6 Mar 2026−2.0%
13 Mar 2026+0.7%
20 Mar 2026+0.7%
27 Mar 2026−3.6%
2 Apr 2026−7.5%
10 Apr 2026+2.6%
17 Apr 2026+2.8%
24 Apr 2026+7.9%
30 Apr 2026+16.4%
8 May 2026+37.8%
15 May 2026+39.2%
22 May 2026+24.8%
29 May 2026+29.2%
4 Jun 2026+42.2%
5 Jun 2026+44.9%
9 Jun 2026+38.1%
10 Jun 2026+37.9%
12 Jun 2026+41.4%
17 Jun 2026+29.9%
19 Jun 2026+32.7%
24 Jun 2026+22.1%
25 Jun 2026+21.2%
1 Jul 2026+3.7%
3 Jul 2026−0.7%
10 Jul 2026+10.1%
17 Jul 2026−0.5%
24 Jul 2026−5.3%
31 Jul 2026−6.5%
7 Aug 2026−0.7%
14 Aug 2026+11.7%
21 Aug 2026+12.8%
28 Aug 2026+10.1%
4 Sep 2026+9.0%
11 Sep 2026+15.5%
18 Sep 2026+15.2%
25 Sep 2026+13.5%
28 Sep 2026+16.0%
1 Oct 2026+9.2%
9 Oct 2026+13.4%
16 Oct 2026+8.0%
23 Oct 2026+12.0%
30 Oct 2026+14.7%
6 Nov 2026+0.2%
13 Nov 2026−6.0%
Each bar is one week, from 2021 to now (264 weeks with a reading). Green means the stock's return over the previous 13 weeks beat the NIFTY 500; red means it trailed. The colour is strongest at a gap of 25 percentage points or more. A gap means there is no reading for that week.

Over the last 5.2 years the share price moved +125% while the NIFTY 500 moved +56%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 6 November 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

What changed at Vijaya Diagnostic Centre this quarter?

Three changes stood out: foreign funds (FIIs) cut their stake for 5 quarters in a row, indian funds and insurers (DIIs) raised their stake for 6 quarters in a row and revenue up on a year earlier for 12 quarters in a row (every quarter we can compare).

  1. Foreign funds (FIIs) cut their stake for 5 quarters in a row

    From 19.6% to 10.7% of the company by the September 2026 quarter.

  2. Indian funds and insurers (DIIs) raised their stake for 6 quarters in a row

    From 23.7% to 32.5% of the company by the September 2026 quarter.

  3. Revenue up on a year earlier for 12 quarters in a row (every quarter we can compare)

    In the September 2026 quarter revenue was ₹255 crore, +26.2% on a year earlier.

What are Vijaya Diagnostic Centre's latest quarterly results?

For July to September 2026 (the quarter ended 30 September 2026), Vijaya Diagnostic Centre reported revenue of ₹255 crore, up 26.2% from ₹202 crore a year earlier, and a profit of ₹59.0 crore, up 37.2% from ₹43.0 crore.

Vijaya Diagnostic Centre results: July to September 2026 against a year earlier

Vijaya Diagnostic Centre results: July to September 2026 against a year earlier
MeasureJuly to September 2026July to September 2025Change
Revenue₹255 crore₹202 crore+26.2%
Profit₹59.0 crore₹43.0 crore+37.2%
Earnings per share₹5.77₹4.21+37.1%
Operating margin44.3%40.6%+3.7 points

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

The newest call in our records is from 7 August 2026, about April to June 2026; a call about these results is not in our records yet.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

What is the Vijaya Diagnostic Centre share price history?

Vijaya Diagnostic Centre closed at ₹1,410.10 on 13 November 2026, up 33.0% from ₹1,060.40 a year earlier (14 November 2025) and up 149.3% over five years. Its highest weekly close since September 2021 was ₹1,558.90 on 18 September 2026.

Vijaya Diagnostic Centre share price: then and now

Vijaya Diagnostic Centre share price: then and now
WhenCloseChange to 13 Nov 2026
1 week ago · 6 Nov 2026₹1,468.60−4.0%
1 month ago · 13 Oct 2026₹1,406.50+0.3%
6 months ago · 15 May 2026₹1,329.20+6.1%
1 year ago · 14 Nov 2025₹1,060.40+33.0%
3 years ago · 12 Nov 2023₹638.75+120.8%
5 years ago · 12 Nov 2021₹565.55+149.3%
Earliest weekly close in our records · 17 Sep 2021₹627.00+124.9%
Highest weekly close since September 2021, also the 52-week high · 18 Sep 2026₹1,558.90−9.5%
Lowest weekly close since September 2021 · 8 Jul 2022₹315.35+347.2%
52-week low (weekly close) · 27 Mar 2026₹870.30+62.0%

Weekly closing prices. Each change is the move from that price to the 13 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

277 weekly closes from 17 September 2021 to 13 November 2026.

What is the latest news on Vijaya Diagnostic Centre?

13 Nov 2026: Vijaya Diagnostic Centre closed at ₹1,410.10, down 4.0% on the week and up 0.3% on the month. Results for July to September 2026: Revenue up 26.2% and profit up 37.2% on a year earlier.

Earlier

  • 16 Sep 2026: ex-date for a dividend of ₹2 a share.
  • Our read, 22 Aug 2026: Revenue and profit grew in the latest quarter while operating margin remained above the stated floor. New hubs are reaching break-even early, supporting the spoke-and-hub rollout beyond Hyderabad.
  • 7 Aug 2026: Vijaya Diagnostic Centre held its results call for April to June 2026.

Our read of the business

Revenue and profit grew in the latest quarter while operating margin remained above the stated floor. New hubs are reaching break-even early, supporting the spoke-and-hub rollout beyond Hyderabad.

Latest quarter: Revenue and profit advanced while operating margin held above the stated floor.

Our read after the latest results, written 22 August 2026.

What dividend does Vijaya Diagnostic Centre pay?

Vijaya Diagnostic Centre paid ₹2 a share in regular dividends in the 12 months to 13 November 2026 (1 payment), a yield of 0.14% at the ₹1,410.10 close on 13 November 2026. The last was a dividend of ₹2 a share, ex-date 16 September 2026.

Vijaya Diagnostic Centre dividends since 1 April 2021

Vijaya Diagnostic Centre dividends since 1 April 2021
Ex-dateDividend per shareTypeRecord date
16 Sep 2026Dividend₹2Dividendsame day
29 Aug 2025Dividend₹2Dividendsame day
30 Aug 2024Dividend₹1Dividendsame day
13 Sep 2023Dividend₹1Dividendsame day
20 Sep 2022Dividend₹1Dividend21 Sep 2022

Amounts as the company declared them on the exchange. A dividend goes to whoever owns the shares before the ex-date.

4 of 5Of the last 5 financial years, years with an exchange dividend record

Yes. Vijaya Diagnostic Centre Ltd paid out 12% of its profit as dividends in FY26, and it paid a dividend in 5 of its last 9 reported years.

From the exchange corporate-actions record, read 13 November 2026.

What did Vijaya Diagnostic Centre management say on the latest results call?

Vijaya Diagnostic Centre has reported its July to September 2026 results since this read was written. The earlier read is kept below, closed, until we update it.

Show the earlier read

On the call for April to June 2026, held on 7 August 2026, Vijaya Diagnostic Centre's management guided: Next-12-month expansion: nine hubs, including two in Pune, 10-12 spokes and Pune backend infrastructure.

Narasimha Raju, on the call for April to June 2026

What management guided

  • FY27 capital spending ₹190-195 crore, including ₹8-10 crore for Andhra land and the Punjagutta laboratory.
  • Operating margin above 40% despite potential expansion drag.
  • FY27 revenue growth high double-digit.
  • Sustainable growth of 15% over 3-5 years viewed achievable.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 7 August 2026.

What is the future of Vijaya Diagnostic Centre? What is changing in the business?

What is changing at Vijaya Diagnostic Centre, from the latest results and calls: mature-cluster operating leverage, phased network expansion and wellness and integrated b2c mix.

  • Mature-cluster operating leverage. Mature centers and early hub break-even can absorb fixed costs as volume rises. ⚠ estimate
  • Phased network expansion. Planned hubs, spokes and backend infrastructure widen the addressable network beyond Hyderabad. ⚠ estimate
  • Wellness and integrated B2C mix. Integrated wellness and imaging packages can add volume and realization without relying on broad price hikes. ⚠ estimate
  • Cash-funded buildout. Operating cash generation can fund the current expansion cycle, though free cash flow remains limited while capital spending is elevated. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown.

Our read after the latest results, written 22 August 2026.

What could change the Vijaya Diagnostic Centre story? What are the risks?

The thesis breaks if the next two reported quarters show revenue growth below the management growth aspiration while operating margin falls below the stated floor, because that would show that new-network spending is not being absorbed by mature-cluster operating leverage.

Each change stops working if

  • Mature-cluster operating leverage: Mature-center growth slows while new-hub losses rise for two consecutive quarters.
  • Phased network expansion: Commissioning slips or the reported network count remains unreconciled.
  • Wellness and integrated B2C mix: Package demand weakens or discounting rises materially.
  • Cash-funded buildout: Operating cash conversion falls while capital spending remains elevated.

The main risks

  • Capital spending and guidance credibility: Capital-spending guidance rose while the rollout count requires reconciliation. ✓ fact
  • Price-action deferral: The intended selective price increase was deferred beyond the earlier timing indication. ✓ fact
  • Hyderabad concentration and seasonality: The largest geography remains material to group growth and past results show seasonal sensitivity. ✓ fact
  • Working-capital interpretation: Working-capital days look elevated in one durability signal, while cash decomposition points to stable component days and capital spending-led cash use. ⚠ estimate

Our read after the latest results, written 22 August 2026.

What to watch in Vijaya Diagnostic Centre's next results?

When Vijaya Diagnostic Centre reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Next hub and spoke commissioning - check whether phased additions stay within the expansion schedule and preserve operating leverage.

Vijaya Diagnostic Centre: what to watch next quarter
What to check (from the call)
Next hub and spoke commissioning - check whether phased additions stay within the expansion schedule and preserve operating leverage.
Punjagutta and Bengaluru laboratory accreditation - check whether backend capacity unlocks the planned network and home-collection rollout.
Andhra land purchase - check whether the owned-site exception advances the planned tier-2 hub without changing the leasing model.
Pune PH backend buildout - check whether capacity constraints ease and network growth broadens beyond the existing base.

Which stock lists is Vijaya Diagnostic Centre on?

Vijaya Diagnostic Centre is on 2 of our India lists: Momentum stocks and Small & mid cap stocks.

Is Vijaya Diagnostic Centre profitable?

Vijaya Diagnostic Centre Ltd earned ₹59.0 Cr of net profit in the Sep 2026 quarter, +37.2% on the same quarter a year earlier. That is the 12th quarter in a row of profit growth. Full-year FY26 profit was ₹173 Cr. Over 8 years profit has grown 22.1% a year on average. The same quarter a year earlier earned ₹43.0 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The Sep 2026 quarter's profit is 23.1% of that quarter's revenue.

For the full year, FY26 profit was ₹173 Cr (+20.1% on the year before).

Why profit moved: revenue changed +26.2% on a year earlier and the margin moved +3.7 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +33.3% and revenue +24.3%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

How much revenue does Vijaya Diagnostic Centre make, and is it growing?

Vijaya Diagnostic Centre Ltd reported ₹255 Cr of revenue in the Sep 2026 quarter, +26.2% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 8 years it has grown 15.8% a year on average. The last full year, FY26, came in at ₹814 Cr.

Revenue is everything the company billed its customers in the period.

Why this happened. Cash conversion exceeds profit on both reported windows. The cash triangle shows that capex, rather than operating leakage, is the main use of operating cash.

The last four reported quarters add to ₹910 Cr.

FY26 revenue was ₹814 Cr, +19.5% on the year before.

Recent pace: the last four quarters grew +24.3% on average, against 15.8% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +24.3%, against +20.5% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +33.6%, against +23.1% a year (accelerating).

Watch next

Metric
Cash-funded buildout
Threshold
Operating cash conversion falls while capex remains elevated.
Which result
the next result

How much of every ₹100 of sales does Vijaya Diagnostic Centre keep?

Vijaya Diagnostic Centre Ltd's operating margin was 44.3% in the Sep 2026 quarter, 3.7 percentage points higher than the same quarter a year ago. Across 9 years it has been between 31.9% and 44.2%. The latest quarter is above every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why this happened. The operating-leverage catapult applies because management attributes margin protection to fixed-cost absorption and phased launches. The read fails if new centers add costs faster than mature clusters add volume.

Why the margin moved: operating margin changed +3.5 percentage points on the year while gross margin changed +1.0 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Watch next

Metric
Mature-cluster operating leverage
Threshold
Mature-center growth slows while new-hub losses rise for two consecutive quarters.
Which result
the next result

Is Vijaya Diagnostic Centre's profit turning into cash?

Over the last 3 years, 155% of Vijaya Diagnostic Centre Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹271 Cr of operating cash against ₹173 Cr of profit. After ₹183 Cr of spending on assets, ₹88.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 155% of profit came in as cash: the cash cycle stayed about the same between FY21 and FY26, so the cash follows profit, not the cycle.

What to look at next: the bigger use of cash is spending on new assets, at 1.7× depreciation over three years. The next section checks what that spending is building.

Where does Vijaya Diagnostic Centre's cash go?

Vijaya Diagnostic Centre Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −117 days in FY26, up from −118 days in FY21. It spent ₹367 Cr on assets over the last 3 years. Customers take 9 days to pay, and stock sits for 19 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹814 Cr, each day of that cycle ties up about ₹2.2 Cr, so roughly −₹261 Cr is tied up in the business at any time.

FY26: customers took 9 days to pay and stock sat for 19 days, about 0.6 months of sales sitting as stock, for a full cycle of −117 days, longer than FY21's −118.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 19 days. Customers pay about 9 days after that. Suppliers are paid at 145 days. Together that makes the −117-day cycle.

Spending on assets: ₹367 Cr over the last 3 years, against ₹220 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹35.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

What is Vijaya Diagnostic Centre's P/E ratio, and how does it compare with its own history?

Vijaya Diagnostic Centre Ltd's P/E is 71.3×, near the high end of its own history: higher than 71% of past readings. Its usual P/E (the middle reading) is 66.2×, over 5.1 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

71.3×P/E · higher than 71% of its last 5.1 years
2.59PEG · today, derived from 3-year earnings growth

Why the multiple is where it is: over the past year earnings per share moved +33.7% while the price moved +33.0%. Earnings did better than the price, which pulled the multiple down within its own range.

Where the price move came from: over 5 years the price moved +20.0% a year; about +19.1% a year came from earnings growth and about +0.9 percentage points from the multiple (roughly no change). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

What growth does the Vijaya Diagnostic Centre share price assume?

Worked out from its price on 24 August 2026, Vijaya Diagnostic Centre Ltd's share price assumed profit growth of about 34.6% a year. Over the past 8 years its profit actually grew 22.1% a year. Today its P/E is 71.3×, higher than 71% of its own last 5.1 years.

This works the share price backwards. It asks one question: what yearly profit growth does the price already assume? The answer is the growth rate at which eleven years of profit (six years of growth, then five years of slowing) add up to that day's market value, after each year is discounted at 11%.

This is a one-day reading, taken on 24 August 2026. Every other number on this page, the multiple included, uses the latest price as of 13 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements.

Is the Vijaya Diagnostic Centre business getting better or worse?

Vijaya Diagnostic Centre Ltd's business is growing steadily. Revenue, profit and EPS growth have stayed positive throughout, and ROCE is steady at 22.3% (four quarters to Sep 2026). This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Steady highRevenue growth · latest (Sep 2026) +24.3%, range +13.2% to +29.0%
RisingProfit growth · latest (Sep 2026) +33.6%, range +11.9% to +42.9%
RisingEPS growth · latest (Sep 2026) +33.7%, range +12.3% to +40.3%
Steady highROCE · latest (four quarters to Sep 2026) 22.3%, range 20.8% to 23.2%

Why it matters: steady growth with healthy returns is how a business compounds over time.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Compound annual growth rate (%)
Measure1yr3yr5yr10yr
Revenue+19.5%+21.0%+16.6%—
Profit+20.1%+26.7%+15.3%—
EPS+20.0%+26.6%+15.2%—
Share price+33.0%+30.2%+20.0%—
+26.2%Revenue growth (Sep 2026) · latest quarter against a year ago
+37.2%Profit growth (Sep 2026) · latest quarter against a year ago
15.8%Revenue, 8 years · yearly growth over the long run

What is the Vijaya Diagnostic Centre story, and has it been checked?

Vijaya Diagnostic Centre Ltd's story is not scored yet against the checks our research set on 22 August 2026.

NOT YET CHECKED

From the numbers. The normalized read confirms the premium rather than reversing it: margin is above its mid-cycle level and normalized…

From the price. Price stage 2, week 26, above its 200-day line, relative strength falling.

What is not proven yet. The thesis breaks if the next two reported quarters show revenue growth below the management growth aspiration while operating margin falls below the stated floor, because that would show that new-network spending is not being absorbed by mature-cluster operating leverage.

The test written in advance. Capex and guidance credibility. Measured by: Capex and guidance credibility FY27_capex ytd cr by the next result.

What the company does. Revenue and profit grew in the latest quarter while operating margin remained above the stated floor. New hubs are reaching break-even early, supporting the spoke-and-hub rollout beyond Hyderabad.

The key numbers to watch, and the level that would change the picture

The key numbers to watch, and the level that would change the picture
MeasureNowWhy it mattersWhat to watch
Mature-cluster operating leverageHIGHMature centers and early hub break-even can absorb fixed costs as volume rises.Mature-center growth slows while new-hub losses rise for two consecutive quarters.
Phased network expansionHIGHPlanned hubs, spokes and backend infrastructure widen the addressable network beyond Hyderabad.Commissioning slips or the reported network count remains unreconciled.
Wellness and integrated B2C mixMEDIUMIntegrated wellness and imaging packages can add volume and realization without relying on broad price hikes.Package demand weakens or discounting rises materially.
Cash-funded buildoutMEDIUMOperating cash generation can fund the current expansion cycle, though free cash flow remains limited while capex is elevated.Operating cash conversion falls while capex remains elevated.

Everything further down this page is evidence for or against these.

The pricerising, above the 200-day averageFY26-Q2 to FY27-Q1

FY26-Q2FY27-Q1

What the surface reading misses. The surface reading is: Jun 2026 was the highest revenue and net-profit quarter in the supplied eight-quarter series. The research reads it further: The higher quarter is accompanied by 43% operating margin, so the revenue advance did not require a collapse in reported operating profitability.

What the surface reading misses. The surface reading is: Revenue growth was 22.9% and net-profit growth was 35.9% year on year in Jun 2026. The research reads it further: Profit grew faster than revenue, consistent with reported operating leverage rather than a revenue-only expansion.

  • 1 · Operating leveragebuilding
  • 2 · Value-added mixquiet
  • 3 · Management changebuilding
  • 4 · Paying down debtquiet
  • 5 · Regulatory approvalbuilding
  • 6 · Order-book winsquiet
  • 7 · Consolidationbuilding
  • 8 · Demerger or value unlockquiet
  • 9 · Buybackquiet
  • 10 · New geographiesquiet
  • 11 · More business from existing customersquiet
  • 12 · New product launchquiet
  • 13 · Mandatory normsquiet
  • 14 · A bigger market to servequiet
  • 15 · Market-share gainsquiet
  • 16 · Asset qualityquiet

Lever 1 · Operating leverage: building. Mature centers and early hub break-even can absorb fixed costs as volume rises. What proves it keeps working: Mature-cluster operating leverage. It stops working if Mature-center growth slows while new-hub losses rise for two consecutive quarters.

Lever 3 · Management change: building. Planned hubs, spokes and backend infrastructure widen the addressable network beyond Hyderabad. What proves it keeps working: Phased network expansion. It stops working if Commissioning slips or the reported network count remains unreconciled.

Lever 5 · Regulatory approval: building. Integrated wellness and imaging packages can add volume and realization without relying on broad price hikes. What proves it keeps working: Wellness and integrated B2C mix. It stops working if Package demand weakens or discounting rises materially.

Lever 7 · Consolidation: building. Operating cash generation can fund the current expansion cycle, though free cash flow remains limited while capex is elevated. What proves it keeps working: Cash-funded buildout. It stops working if Operating cash conversion falls while capex remains elevated.

Sources: our stock research file (22 August 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.

The whole page in one table. Each row links to its section.

The whole page in one table. Each row links to its section.
SectionWhere it is nowThe one thing to watch next
Margin44%Mature-cluster operating leverage
Ownershipsee the sectionPhased network expansion
Safetysee the sectionWellness and integrated B2C mix
Revenue₹255 CrCash-funded buildout

Did Vijaya Diagnostic Centre management deliver what it promised?

What Vijaya Diagnostic Centre Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.

Planned Price Increase Deferred · 7 August 2026. In May 2026, management said it would take roughly a 1% to 1.5% price hike in Q1 or Q2. In Aug 2026, management said no hike had been taken since the prior increase and that pricing would only be reassessed after Q2 and Q3, moving beyond the previously stated timing without explaining the delay; this changes realization assumptions.

Reported Center Count Does Not Reconcile With Additions · 7 August 2026. May 2026 reported 162 centers. By Aug 2026, management reported 166 centers but also said two hubs and six spokes had been commissioned to date, which would imply 170 centers from the prior reported base before any closures or reclassifications. The latest call did not explain the discrepancy, which matters for tracking network rollout and capex productivity.

FY27 Capital Expenditure Guidance Materially Revised Upward · 8 May 2026. Management consistently guided FY27 capital expenditure at INR 100-120 crores in both the Nov 2025 and Feb 2026 calls, covering the same planned expansion of 4-5 hubs and 10-12 spokes. In the May 2026 call, this was revised upward to INR 140-150 crores - a 17-50% increase - with management citing a new automated lab at Punjagutta, Hyderabad and higher center-level costs; the Punjagutta lab project had not been mentioned in either prior call, and the per-center capex for the same hub and spoke count also appears to have increased from the prior guided range. This unexplained revision would materially impact free cash flow projections and capital allocation models.

Expansion Strategy De-acceleration · 13 February 2026. In the November 2025 call, management signaled an aggressive expansion posture, stating that early break-evens in new geographies encouraged them to open "a lot more hubs" than previously planned. However, in the February 2026 call, they pivoted to a conservative stance for FY27, guiding for only 4-5 hubs (down from the 10 planned in FY26) and citing "operational bandwidth" constraints rather than capital availability as the reason to slow down hub additions. Earlier call (Nov 2025): “Bangalore. has broken even much earlier. So, that is kind of encouraging for us to open a lot more hubs than probably what we have mentioned.” Later call (Feb 2026): “For FY27, we will be seeing about 4-5 hubs. It is more in terms of ground-level operational challenges. The decision-making is not based on margin but on operational bandwidth and stabilization.”

Every quote above is taken word for word from the company’s own earnings calls.

What is Vijaya Diagnostic Centre management's track record?

Recurring guidance revisions on an otherwise operationally strong base (operating margin 43.8%)

Regulatory and governance record

No SEBI/CBI/ED action or fraud allegation surfaced; sweep returned only unrelated HDFC insider-trading case.

0%Promoter shares pledged

Checked 21 July 2026.

How much does Vijaya Diagnostic Centre earn on its capital?

Vijaya Diagnostic Centre Ltd earned a ROCE of 21% in FY26. That is up from a low of 18% in FY23. Its return on capital used (ROIC) is 7.5 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 21.3% net margin and 0.54× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 21.3% net margin × 0.54× asset turnover × 1.57× leverage (assets divided by equity) ≈ 18.1% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 19.5% − 12.0% = +7.5 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value.

Does Vijaya Diagnostic Centre have too much debt?

Vijaya Diagnostic Centre Ltd has total debt of ₹509 Cr against shareholder equity of ₹1,057 Cr as of Sep 2026, so its debt is 0.48× its equity. Year by year, that ratio went from 0.39 in FY22 to 0.44 in FY26. Keep that borrowing in mind when reading the returns on this page.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

What is the Vijaya Diagnostic Centre shareholding pattern?

Domestic institutions raised their stake in Vijaya Diagnostic Centre Ltd by 9.0 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 32.5% of the company. Foreign institutions moved −7.5 points over the same period, to 10.7%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Why this happened. Management has outlined further hub and spoke additions, with Pune backend infrastructure and laboratory accreditation as dependencies. Early break-even evidence supports the rollout, but center-count reconciliation remains a monitoring issue.

Over the last two years: Domestic institutions: +9.0 points over 8 quarters, to 32.5%; Foreign institutions: −7.5 points over 8 quarters, to 10.7%; Promoters: −1.4 points over 8 quarters, to 52.5%.

Why the owners changed: foreign institutions moved −7.5 points and domestic institutions +9.0 points over 8 quarters, while promoters moved −1.4 points. One group of institutions took over shares from the other; it is not a change of mind by the people running the company.

Watch next

Metric
Phased network expansion
Threshold
Commissioning slips or the reported network count remains unreconciled.
Which result
the next result

How far is Vijaya Diagnostic Centre from balance-sheet trouble?

For Vijaya Diagnostic Centre Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why this happened. Management describes pathology and radiology as contributors and identifies wellness demand across retail and corporate customers. This is a mix lever, not a confirmed near-term price lever.

Watch next

Metric
Wellness and integrated B2C mix
Threshold
Package demand weakens or discounting rises materially.
Which result
the next result

How does Vijaya Diagnostic Centre rank in its industry?

66.3 out of 100, rank 2 of 9 in Diagnostics, with 100% of the evidence available.

Vijaya Diagnostic Centre Ltd scores 66.3 out of 100 against the 9 companies it is compared with in Diagnostics, ranking 2. Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.

The four parts add up to the total exactly: 28.3 + 17.5 + 2.3 + 18.2 = 66.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Which companies is Vijaya Diagnostic Centre compared with?

Vijaya Diagnostic Centre ranks 2 of 9 Diagnostics companies on the 4-Factor Sector Score, with 66.3 out of 100.

  1. 1Metropolis Healthcare LtdMETROPOLIS · turning · Most evidence points up · 100% evidence67.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 27.6/35 · Revenue 19.9% · Profit 42.4% · Operating margin change 2 points · 100% evidenceCapital efficiency 14.1/25 · ROCE 17.8% (year to Mar 2026) · Operating margin 27% · 100% evidenceValuation 11.9/20 · P/E 52.1× · PEG 1.94 · 100% evidenceRelative strength 13.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 5% · Strength vs NIFTY 500 (same reading) 8.3% · 1 year 14.5% · 100% evidence · 4 of 12 weeks aheadExact sum: 27.6 + 14.1 + 11.9 + 13.7 = 67.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  2. 2Vijaya Diagnostic Centre Ltd this pageVIJAYA · leader · Most evidence points up · 100% evidence66.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 28.3/35 · Revenue 24.3% · Profit 33.5% · Operating margin change 3 points · 100% evidenceCapital efficiency 17.5/25 · ROCE 20.5% (year to Mar 2026) · Operating margin 44.3% · 100% evidenceValuation 2.3/20 · P/E 71.3× · PEG 2.59 · 100% evidenceRelative strength 18.2/20 · Strength vs its industry (price vs its 52-week average, weekly) 16.5% · Strength vs NIFTY 500 (same reading) 19.4% · 1 year 33% · 100% evidence · 12 of 12 weeks aheadExact sum: 28.3 + 17.5 + 2.3 + 18.2 = 66.3 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
  3. 3One Global Service Provider LtdEvidence leans up · 67% evidence62.5out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 33.1/43.75 · Revenue 100% · Profit 100% · Operating margin change -2.6 points · 95% evidenceCapital efficiency 17.6/31.25 · ROCE 87% (year to Mar 2026) · Operating margin 16.7% · 95% evidenceValuation 11.8/25 · P/E 12.4× · PEG — · 50% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 33.1 + 17.6 + 11.8 = 62.5 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone.
  4. 4Suraksha Diagnostic LtdSURAKSHA · breaking out · Evidence leans up · 89% evidence59.4out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 18.9/35 · Revenue 23% · Profit 9.4% · Operating margin change 2 points · 88% evidenceCapital efficiency 11.7/25 · ROCE 17.3% (year to Mar 2026) · Operating margin 34.1% · 100% evidenceValuation 11.7/20 · P/E 49.7× · PEG 1.79 · 65% evidenceRelative strength 17.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 10.1% · Strength vs NIFTY 500 (same reading) 13.6% · 1 year 10.2% · 100% evidence · 11 of 12 weeks aheadExact sum: 18.9 + 11.7 + 11.7 + 17.1 = 59.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  5. 5Thyrocare Technologies LtdTHYROCARE · quiet · Evidence leans up · 100% evidence57.0out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 21.6/35 · Revenue 22% · Profit 12.6% · Operating margin change 0 points · 100% evidenceCapital efficiency 20.9/25 · ROCE 35.4% (year to Mar 2026) · Operating margin 32.8% · 100% evidenceValuation 8.9/20 · P/E 55× · PEG 2.28 · 100% evidenceRelative strength 5.6/20 · Strength vs its industry (price vs its 52-week average, weekly) -1.5% · Strength vs NIFTY 500 (same reading) 1.3% · 1 year -4.4% · 100% evidence · 6 of 12 weeks aheadExact sum: 21.6 + 20.9 + 8.9 + 5.6 = 57 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  6. 6Dr Lal Pathlabs LtdLALPATHLAB · losing its lead · Evidence leans up · 100% evidence56.4out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 15.8/35 · Revenue 16.7% · Profit 8.7% · Operating margin change 1 points · 100% evidenceCapital efficiency 19.6/25 · ROCE 28% (year to Mar 2026) · Operating margin 32% · 100% evidenceValuation 4.6/20 · P/E 57.1× · PEG 2.79 · 100% evidenceRelative strength 16.4/20 · Strength vs its industry (price vs its 52-week average, weekly) 16.2% · Strength vs NIFTY 500 (same reading) 19.4% · 1 year 26.4% · 100% evidence · 11 of 12 weeks aheadExact sum: 15.8 + 19.6 + 4.6 + 16.4 = 56.4 · What this means: Relative strength against the index is 19.4%, and revenue and profit growth are weak.
  7. 73B Blackbio DX Ltd3BBLACKBIO · breaking out · Evidence leans down · 78% evidence49.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 15.8/35 · Revenue 54.3% · Profit 14.7% · Operating margin change -27.8 points · 83% evidenceCapital efficiency 16.0/25 · ROCE 25.5% (year to Mar 2026) · Operating margin 25.4% · 76% evidenceValuation 10.2/20 · P/E 20.7× · PEG — · 50% evidenceRelative strength 7.3/20 · Strength vs its industry (price vs its 52-week average, weekly) -9.6% · Strength vs NIFTY 500 (same reading) -6.3% · 1 year -3.6% · 100% evidence · 11 of 12 weeks aheadExact sum: 15.8 + 16 + 10.2 + 7.3 = 49.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  8. 8Krsnaa Diagnostics LtdKRSNAA · quiet · Evidence leans down · 75% evidence41.8out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 10.9/35 · Revenue 15.9% · Profit 16.5% · Operating margin change -3 points · 100% evidenceCapital efficiency 8.8/25 · ROCE 12.7% (year to Mar 2026) · Operating margin 26.2% · 100% evidenceValuation 14.6/20 · P/E 17.5× · PEG — · 50% evidenceRelative strength 7.5/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) -23.5% · 1 year -34.4% · 25% evidence · 1 of 12 weeks aheadExact sum: 10.9 + 8.8 + 14.6 + 7.5 = 41.8 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far.
  9. 9Vimta Labs LtdVIMTALABS · quiet · Most evidence points down · 90% evidence34.0out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 8.1/35 · Revenue 11.7% · Profit 2.5% · Operating margin change 0 points · 100% evidenceCapital efficiency 15.7/25 · ROCE 25.2% (year to Mar 2026) · Operating margin 33.9% · 100% evidenceValuation 9.1/20 · P/E 27.7× · PEG — · 50% evidenceRelative strength 1.1/20 · Strength vs its industry (price vs its 52-week average, weekly) -11.9% · Strength vs NIFTY 500 (same reading) -9.1% · 1 year -21.9% · 100% evidence · 7 of 12 weeks aheadExact sum: 8.1 + 15.7 + 9.1 + 1.1 = 34 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Diagnostics, all 9 compared on one page.

Which companies are close to Vijaya Diagnostic Centre in size?

Vijaya Diagnostic Centre is the 2nd largest of 9 Diagnostics companies on Sector Alpha by market value (at the 13 November 2026 close). Just above it: Dr Lal Pathlabs. Just below it: Metropolis Healthcare, Thyrocare Technologies, Vimta Labs, Suraksha Diagnostic and Krsnaa Diagnostics.

Diagnostics companies close in size

  1. Dr Lal Pathlabs Ltd ₹33,453 crore
  2. Vijaya Diagnostic Centre Ltd ₹14,523 crore
  3. Metropolis Healthcare Ltd ₹11,709 crore
  4. Thyrocare Technologies Ltd ₹7,930 crore
  5. Vimta Labs Ltd ₹2,230 crore
  6. Suraksha Diagnostic Ltd ₹1,779 crore
  7. Krsnaa Diagnostics Ltd ₹1,715 crore

All 9 Diagnostics companies, largest first

Companies close in size in other industries

  1. Niva Bupa Health Insurance Company Ltd ₹14,578 crore · Finance - Insurance
  2. Ramkrishna Forgings Ltd ₹14,562 crore · Castings, Forgings & Fastners
  3. Vijaya Diagnostic Centre Ltd ₹14,523 crore
  4. Shaily Engineering Plastics Ltd ₹14,485 crore · Plastics - Plastic & Plastic Products
  5. Juniper Green Energy Ltd ₹14,466 crore

What else do people ask about Vijaya Diagnostic Centre?

What is Vijaya Diagnostic Centre's share price today?

Vijaya Diagnostic Centre Ltd's share price is ₹1,410.10, +33.0% over the past year. The whole company is worth ₹14,520 Cr on the market.

In the last 52 weeks it traded between ₹870 to ₹1,559; today it is 78% of the way up from the low, 8.7% above its 200-day average (as of 13 November 2026).

What were Vijaya Diagnostic Centre's latest quarterly results?

Vijaya Diagnostic Centre Ltd reported revenue of ₹255 Cr and net profit of ₹59.0 Cr for the Sep 2026 quarter. Revenue rose 26.2% and profit rose 37.2% compared with a year earlier. Earnings per share were ₹5.77.

The operating margin was 44.3%, 3.7 percentage points higher than a year earlier (as of 13 November 2026).

What is Vijaya Diagnostic Centre's market cap?

Vijaya Diagnostic Centre Ltd's market capitalisation is ₹14,520 Cr at a share price of ₹1,410.10. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 13 November 2026).

How is Vijaya Diagnostic Centre performing?

Vijaya Diagnostic Centre Ltd's share price has been rising for 26 weeks. In its latest quarter, revenue rose 26.2% and profit rose 37.2% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 1 week running (as of 13 November 2026).

Will Vijaya Diagnostic Centre's share price go up?

This page does not forecast Vijaya Diagnostic Centre Ltd's share price. What it shows instead: the share price is ₹1,410.10, and it has been rising for 26 weeks. Its P/E of 71.3× is higher than 71% of its own last 5 years (as of 13 November 2026).

Where is Vijaya Diagnostic Centre in its business cycle?

Vijaya Diagnostic Centre Ltd's FY26 operating margin was 41.4%, against a 9-year range of 31.9% to 44.2%. The latest quarter was 44.3%, above the top of its own yearly range in the latest quarter, so margins are at a high and the story depends on them staying there.

Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 13 November 2026).

What could break the Vijaya Diagnostic Centre story?

The main question: foreign institutions moved −7.5 percentage points over 8 quarters while the business went the other way. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 13 November 2026).

Is Vijaya Diagnostic Centre a stock worth studying right now?

What the numbers show: Vijaya Diagnostic Centre Ltd's earnings have grown faster than its share price. Earnings per share grew +33.7% in a year while the price moved +33.0%. The main open question: whether the owners’ moves turn back in line with the business.

Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 13 November 2026).

Is there a Vijaya Diagnostic Centre share price forecast for 2026?

What is changing at Vijaya Diagnostic Centre, from the latest results and calls: mature-cluster operating leverage, phased network expansion and wellness and integrated b2c mix.

What would change the story: The thesis breaks if the next two reported quarters show revenue growth below the management growth aspiration while operating margin falls below the stated floor, because that would show that new-network spending is not being absorbed by mature-cluster operating leverage.

Where does this page get Vijaya Diagnostic Centre's management information?

From Vijaya Diagnostic Centre's results calls, its filings and public records on governance, each dated on the page. Management’s plans are shown as plans, never as results.

Where do these numbers come from?

Sector Alpha, written by code from the published numbers. Data as of 13 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.

More lists

Every Sector Alpha list, grouped

X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.